- Conditions
- Localized Prostate Cancer
- Interventions
- TOOKAD Soluble 4 mg/kg
- Drug
- Lead sponsor
- Steba Biotech S.A.
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Localized Prostate Cancer
- Interventions
- TOOKAD®
- Drug
- Lead sponsor
- Steba Biotech S.A.
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Peripheral Lung Tumor
- Interventions
- Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
- Combination Product
- Lead sponsor
- Impact Biotech Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- STAKEL
- Drug
- Lead sponsor
- Steba Biotech S.A.
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • West Columbia, South Carolina • Harlingen, Texas
- Conditions
- Transitional Cell Cancer of Renal Pelvis and Ureter
- Interventions
- padeliporfin VTP
- Drug
- Lead sponsor
- Steba Biotech S.A.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 12
- States / cities
- Irvine, California • Los Angeles, California • Atlanta, Georgia + 9 more
- Conditions
- Locally Advanced Unresectable Pancreatic Adenocarcinoma
- Interventions
- Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
- Combination Product
- Lead sponsor
- Impact Biotech Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Duarte, California • Irvine, California